Natixis Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Natixis Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-13,765	Closed	-$133K	–	1319
2014 Q2	$133K	Buy	13,765 +173	+1%	+$1.54K	﹤0.01%	1300
2014 Q1	$113K	Sell	13,592 -212	-2%	-$1.82K	﹤0.01%	1231
2013 Q4	$117K	Buy	13,804 +455	+3%	+$3.83K	﹤0.01%	1142
2013 Q3	$106K	Sell	13,349 -541	-4%	-$4.35K	﹤0.01%	1098
2013 Q2	$107K	Buy	+13,890	New	+$108K	﹤0.01%	1044

Other funds holding PDLI

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Natixis Advisors's PDLI Position: Q3 2014 in Review

Natixis Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q3 2014, closing a stake of 13,765 shares — an estimated $133K sold.

Natixis Advisors first reported a position in PDLI in Q2 2013 and held it in 5 quarters. The position peaked at $133K in Q2 2014. 231 funds tracked by Wall St. Rank hold PDLI as of Q3 2014.

Natixis Advisors reported no remaining PDL BioPharma, Inc. position as of Q3 2014 after selling out during the quarter.
Natixis Advisors sold 13,765 PDL BioPharma, Inc. shares in Q3 2014, an estimated $133K.
Natixis Advisors first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 5 quarters.
Natixis Advisors's PDL BioPharma, Inc. position peaked at $133K in Q2 2014.
231 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2014.

Based on Natixis Advisors's 13F filing for Q3 2014, filed 3 Nov 2014.